Clinical Trial Detail

NCT ID NCT03661632
Title An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Bristol-Myers Squibb
Indications

Advanced Solid Tumor

colorectal cancer

pancreatic cancer

triple-receptor negative breast cancer

lung non-small cell carcinoma

Therapies

BMS-986310 + Nivolumab

Age Groups: senior adult

No variant requirements are available.